TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7917797
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg twice daily
Study: 10463514
Drug: Amoxicillin/clavulanate 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500/125 mg 3 times daily
Study: 2562010
Drug: Fluxum (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluxum (low molecular weight heparin)
Study: 2562010
Drug: Calcium-heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-heparin
Study: 853979
Drug: bivalent iron
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent iron sulfate (quick release stick capsule preparation)
Study: 853979
Drug: trivalent iron
Normalized name: Iron trivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: trivalent iron citrate complex preparations
Study: 853979
Drug: ferric iron
Normalized name: FERRIC IRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferric iron preparations
Study: 28735202
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no exercise therapy)
Study: 25926562
Drug: Intra-myocardial injections
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-myocardial injections of MSC
Study: 17328961
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group cognitive therapy (IGCT)
Study: 21763101
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group cognitive therapy (IGCT) and Individual cognitive therapy (ICT)
Study: 16786421
Drug: EmbryoGlue treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EmbryoGlue treatment prior to embryo transfer
Study: 14557172
Drug: Oral acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetylsalicylate
Study: 14557172
Drug: Oral pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline
Study: 14557172
Drug: Topical beta-blocker
Normalized name: Beta-HC Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beta-blocker
Study: 8639370
Drug: Smoking reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking reduction advice in combination with dental health instruction and periodontal care
Study: 6234335
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% erythromycin/1.2% zinc acetate solution
Study: 31295391
Drug: Hydrofluoric acid
Normalized name: Hydrofluoric acid
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrofluoric acid treatment [9.6% HF (Pulpdent) for 2 minutes]
Study: 29864437
Drug: Partial gland
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial gland ablation with vascular targeted photodynamic therapy
Study: 25777270
Drug: Cognitive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive intervention (two weekly 1-hour therapy sessions)
Study: 25176361
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg orally one hour before surgery and then every 12 hours for the first 24 hours after surgery
Study: 22488231
Drug: 65 g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 g/L carbohydrate (trial C)
Study: 22488231
Drug: 50 g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/L carbohydrate and 15 g/L whey protein isolate (trial CP)
Study: 12161513
Drug: Metyrapone treatment
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone treatment followed by hydrocortisone replacement in elderly subjects with moderate cortisol levels (n = 8)
Study: 12161513
Drug: Hydrocortisone treatment
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone treatment in elderly subjects with high cortisol levels (n = 9)
Study: 12161513
Drug: Metyrapone treatment
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone treatment in elderly subjects with high cortisol levels (n = 9)
Study: 8558936
Drug: IL-3 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-3 (all doses combined)
Study: 8558936
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events during IL-3 and chemotherapy
Study: 6341045
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg three times daily for seven days
Study: 6341045
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg three times daily for seven days
Study: 28904319
Drug: Low-molecular-weight chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight chitosan solution
Study: 15262418
Drug: Nystatin suspension
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin suspension
Study: 16680252
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid (10 mg x kg(‐1))
Study: 10862158
Drug: rhDNase (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase (2.5 mg qd)
Study: 9322569
Drug: Oral thiamine
Normalized name: thiamine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thiamine (10 mg/d)
Study: 8383578
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at 1 g/day
Study: 29376886
Drug: scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: scalp acupuncture + low frequency rTMS + routine rehabilitation treatment
Study: 29376886
Drug: scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: scalp acupuncture + routine rehabilitation treatment
Study: 26803187
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiotherapy (IMRT) and Concomitant Chemotherapy (CCT)
Study: 19013300
Drug: Glucose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (25 g)
Study: 20533761
Drug: Loratadine/montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine/montelukast (10 mg/10 mg)
Study: 11297959
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg daily elemental zinc)
Study: 7509243
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 to 10 mg once daily for 24 weeks)
Study: 7509243
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 24 weeks)
Study: 3080693
Drug: TRH 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH 150 mg subcutaneous injection
Study: 3080693
Drug: TRH 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH 500 mg IV infusion
Study: 29987899
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control Group E)
Study: 27133819
Drug: ATRA and
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA and chemotherapy (CHT)
Study: 24497338
Drug: Antiarrhythmic Drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic Drugs (AAD)
Study: 22064737
Drug: Avilamycin (44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avilamycin (44 mg/kg)
Study: 22064737
Drug: Rosemary essential
Normalized name: EUCALYPTOL 2.4 g in 100 g TOPICAL LIQUID [MELAO ROSEMARY ESSENTIAL Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosemary essential oil (100 mg/kg)
Study: 22064737
Drug: Oregano essential
Normalized name: Oregano
DrugBank: Oregano (DB10677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregano essential oil (100 mg/kg)
Study: 22064737
Drug: Rosemary and
Normalized name: Aspercreme Max Strength-Lidocaine Rosemary and Mint Roll-On
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosemary and oregano essential oils (50 mg each/kg)
Study: 22064737
Drug: Commercial blend
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial blend of essential oils (1,000 mg/kg)
Study: 11218894
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 10% glucose 500 ml + danshen compound 14 ml + low molecular weight dextran 500 ml i.v.
Study: 11218894
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 10% glucose 500 ml + danshen compound 14 ml + low molecular weight dextran 500 ml i.v. + 25% magnesium sulfate 20 ml in 5% glucose 500 ml i.v.
Study: 11218894
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: no treatment given.
Study: 3034017
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg once daily
Study: 8458057
Drug: Placebo 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5 mg once daily
Study: 2957124
Drug: Upper arm
Normalized name: A And D Medical UA-651 Upper Arm BPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper arm injection of 20 micrograms LHRH
Study: 2957124
Drug: Lower abdominal
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower abdominal wall injection of 20 micrograms LHRH
Study: 2957124
Drug: Order of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Order of injections (upper arm first vs lower abdominal wall first)
Study: 28577666
Drug: 6-month dual
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month dual antiplatelet therapy (DAPT) after Resolute Integrity stent implantation
Study: 29104179
Drug: 12-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12-month dual antiplatelet therapy (DAPT)
Study: 19027814
Drug: Trilucent breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trilucent breast implants (TBI)
Study: 3584738
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (23 g/d for 4 weeks)
Study: 3584738
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid (23 g/d for 4 weeks)
Study: 29669883
Drug: Erythromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (400 mg, twice daily for 48 weeks)
Study: 28854973
Drug: CCH 0.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH 0.40 mg
Study: 28854973
Drug: CCH 0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH 0.60 mg
Study: 28854973
Drug: CCH 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH 0.25 mg
Study: 28854973
Drug: CCH (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH (all doses)
Study: 28854973
Drug: CCH 0.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH 0.40 mg and 0.60 mg
Study: 23977864
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with blueberries (150 g on exercise days)
Study: 21263103
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) program, 20 two-hour sessions over 1 year, median attendance 85%
Study: 12755536
Drug: Simethicone-coated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone-coated cellulose (SCC) 800 mL
Study: 12755536
Drug: Water 800
Normalized name: theophylline in dextrose 5 % in water 800 mg/L INTRAVEN INTRAVENOUS SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 800 mL
Study: 7662242
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily, titrated to 100 mg if blood pressure uncontrolled after 6 weeks
Study: 7662242
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once daily, titrated to 100 mg if blood pressure uncontrolled after 6 weeks
Study: 28831250
Drug: Pulmonary Daoyin
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary Daoyin (PD) program, 3-month, ten times-weekly supervised rehabilitation
Study: 16838873
Drug: Oral-B Indicator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B Indicator 40 toothbrush
Study: 21782353
Drug: Prescription participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription participants (standard care)
Study: 21782353
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Contingency and Prescription)
Study: 18972123
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with paclitaxel (200 mg/m²) and cisplatin (100 mg/m²)
Study: 18972123
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by radiotherapy (69.9 Gy in 5.5 weeks)
Study: 9512672
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by radiotherapy
Study: 16297751
Drug: Balanced inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced inhalation anesthesia (BAL)
Study: 11980997
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (50.4 Gy/28 fractions)
Study: 11980997
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (64.8 Gy/36 fractions)
Study: 1663089
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole for a period of 6-8 weeks
Study: 7078717
Drug: Neutral, emotionally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral, emotionally loaded, and 'mental task' stimuli; specific details on dosage and duration not available.
Study: 31641767
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (ciprofloxacin)
Study: 31641767
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (ceftriaxone)
Study: 28118256
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus amitriptyline (CBT+A)
Study: 26051874
Drug: Empagliflozin 50
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 50 mg alone for 5 days
Study: 26051874
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg coadministered with pioglitazone 45 mg for 7 days
Study: 26051874
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg coadministered with pioglitazone 45 mg for 7 days
Study: 26051874
Drug: Empagliflozin 50
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 50 mg coadministered with pioglitazone 45 mg for 7 days
Study: 26051874
Drug: Empagliflozin and
Normalized name: Empagliflozin and Linagliptin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin and pioglitazone combination treatment
Study: 26051874
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg alone for 7 days
Study: 26051874
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg coadministered with pioglitazone
Study: 26051874
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg coadministered with pioglitazone
Study: 26051874
Drug: Empagliflozin 50
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 50 mg coadministered with pioglitazone
Study: 21735753
Drug: concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: concomitant therapy
Study: 16714852
Drug: Low-dose corticotropin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticotropin stimulation test with 1 microg of 1-24 ACTH intravenously
Study: 16714852
Drug: Decreasing daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreasing daily equipotent doses of inhaled corticosteroids
Study: 11310515
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination tablet (abacavir 300 mg, lamivudine 150 mg, zidovudine 300 mg taken twice/day)
Study: 11310515
Drug: ABC‐COM (abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC‐COM (abacavir 300 mg plus lamivudine 150 mg and zidovudine 300 mg taken twice/day)
Study: 11310515
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination tablet
Study: 12470761
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control treatment
Study: 27490921
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of hydrocortisone (0.4-0.6 mg/kg body weight)
Study: 24861159
Drug: Phonological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonological therapy
Study: 27260592
Drug: Articulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulation therapy
Study: 15939139
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid plus carboplatin (standard administration)
Study: 15939139
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid plus carboplatin (chronomodulated administration)
Study: 15939139
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid (without carboplatin, standard administration)
Study: 15939139
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid (without carboplatin, chronomodulated administration)
Study: 11783243
Drug: Composite salviae
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite salviae dropping pill (CSDP)
Study: 1930035
Drug: 15 minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 minute oxytocin dose escalation
Study: 1930035
Drug: 30 minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minute oxytocin dose escalation
Study: 3883697
Drug: Alaproclate 200
Normalized name: alaproclate
DrugBank: Alaproclate (DB13233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alaproclate 200 mg twice daily
Study: 27428186
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with methotrexate, leflunomide, and hydroxychloroquine for up to 36 weeks
Study: 27428186
Drug: Tapering DMARDs
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering DMARDs treatment after achieving remission (DAS28 ≤ 2.6) and low HAQ (≤ 0.5)
Study: 15170905
Drug: Leflunomide monotherapy
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide monotherapy
Study: 25414593
Drug: Combined psoas
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psoas compartment-sciatic nerve block (PCSNB) using 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine and iliac crest block with 5 mL of the same solution.
Study: 25414593
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anaesthesia (CSA) using 2.5 mg of isobaric bupivacaine 0.5%, with additional doses if sensory block did not reach T12.
Study: 18399947
Drug: Silodosin 4
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 4 mg twice daily for 3 days
Study: 14522414
Drug: Enalapril pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril pre-treatment for 5 days
Study: 14522414
Drug: Enalapril 2
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 2 hours before LPS infusion
Study: 14522414
Drug: Placebo pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pre-treatment for 5 days
Study: 1623802
Drug: T +
Normalized name: RE PreVit + DHA Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T + E (Terbutaline + Enalapril 10 mg)
Study: 1623802
Drug: T +
Normalized name: RE PreVit + DHA Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T + S (Terbutaline + Spironolactone 100 mg)
Study: 19450896
Drug: Low-dose interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interferon-alpha (IFN-alpha)
Study: 16280432
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (300 mL)
Study: 16280432
Drug: Water (control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (control, 300 mL)
Study: 16280432
Drug: Aspartame solution
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame solution (300 mL)
Study: 16280432
Drug: Maltodextrin solution
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin solution (300 mL)
Study: 9617982
Drug: Sibutramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 20 mg
Study: 12502668
Drug: Sibutramine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (both doses)